FOXP3-targeted immune therapy for IPEX
Part of Immune system & allergy clinical trials.
This Phase 1 study tests a gene-targeted immune treatment designed for people with IPEX caused by a FOXP3 gene change. It aims to improve immune control in people whose IPEX symptoms are not well controlled or who cannot safely take standard immune-suppressing medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a FOXP3 gene mutation confirmed
- You should have IPEX with ongoing or worsening symptoms, and you either can’t use immune-suppressing medicine or have symptoms that come back
- If you have had a prior stem cell transplant, your IPEX symptoms have returned and still need immune-suppressing treatment
- You must be able to tolerate the study procedure (including blood collection/leukapheresis if needed) and meet weight and overall health thresholds
- You must not have an active ongoing infection and should have acceptable heart, liver, kidney, and bone marrow function
- You must be able to give consent (or have a legally authorized caregiver consent for a child)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a gene therapy that delivers a correct copy of the FOXP3 gene to your immune cells (T-cells), turning them into cells that can calm the overactive immune response seen in IPEX syndrome. The goal is to reduce symptoms and the need for lifelong immunosuppressive drugs.
This trial tests an experimental injection called Ixovex-1, either alone or with another drug (pembrolizumab), for people with advanced solid tumors that can be injected. It is for those who have run out of standard options and have tumors that are not too deep inside the body.
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
This trial tests a new mRNA-based medicine called RXIM002 for people with immune thrombocytopenia (ITP) that has not improved with standard treatments. The goal is to see if it can safely help raise platelet counts and reduce bleeding risk.
This study tests a new drug called RXIM002 for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if targeting immune cells with the CD19 marker can help control the disease.
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Hear when a new IPEX trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.